Overview of ER+/HER2- Metastatic Breast Cancer (mBC)

Paolo Tarantino, MD, provides an overview of ER-positive, HER2-negative metastatic breast cancer (ER+/HER2- mBC), highlighting the prevalence, patient populations, and the typical prognosis.

Related Videos
Ruth M. O’Regan, MD, professor, chair, Charles Ayrault Dewey Professorship of Medicine, Department of Medicine, the University of Rochester, physician-in-chief, Strong Memorial Hospital, associate director, Education and Mentoring, the Wilmot Cancer Institute at University of Rochester,
Jean Wright, MD
Steven Cai, MD, FACS
Hyman B. Muss, MD
Expert on breast cancer
Priyanka Sharma, MD
Rima Patel, MD
David D'Ambrosio, MD
David Rimm, MD, PhD
Nathalie McDowell Johnson, MD, FACS
Related Content

FDA Approval Sought for Lumisight Optical Imaging Agent to Assist in Intraoperative Breast Cancer Detection

March 21st 2023

FDA Approval Insights: Sacituzumab Govitecan in HR-positive, HER2-negative Breast Cancer

March 20th 2023

Patritumab Deruxtecan Continues to Generate Responses in Previously Treated EGFR-Mutated NSCLC and HER3-Expressing Breast Cancer

March 20th 2023

Nair Notes the Benefits of Yoga as a Complementary Therapy in Nonmetastatic Breast Cancer

January 30th 2023

Response-Guided Therapy Is the Next Frontier for Tailoring Therapy in HER2+ Breast Cancer

March 10th 2023

State of Science Summit- Breast Cancer: Chaired by Jennifer M. Matro, MD

March 9th 2023

FDA Approval Sought for Lumisight Optical Imaging Agent to Assist in Intraoperative Breast Cancer Detection

March 21st 2023

FDA Approval Insights: Sacituzumab Govitecan in HR-positive, HER2-negative Breast Cancer

March 20th 2023

Patritumab Deruxtecan Continues to Generate Responses in Previously Treated EGFR-Mutated NSCLC and HER3-Expressing Breast Cancer

March 20th 2023

Nair Notes the Benefits of Yoga as a Complementary Therapy in Nonmetastatic Breast Cancer

January 30th 2023

Response-Guided Therapy Is the Next Frontier for Tailoring Therapy in HER2+ Breast Cancer

March 10th 2023

State of Science Summit- Breast Cancer: Chaired by Jennifer M. Matro, MD

March 9th 2023

FDA Approval Sought for Lumisight Optical Imaging Agent to Assist in Intraoperative Breast Cancer Detection

March 21st 2023

FDA Approval Insights: Sacituzumab Govitecan in HR-positive, HER2-negative Breast Cancer

March 20th 2023

Patritumab Deruxtecan Continues to Generate Responses in Previously Treated EGFR-Mutated NSCLC and HER3-Expressing Breast Cancer

March 20th 2023

Nair Notes the Benefits of Yoga as a Complementary Therapy in Nonmetastatic Breast Cancer

January 30th 2023

Response-Guided Therapy Is the Next Frontier for Tailoring Therapy in HER2+ Breast Cancer

March 10th 2023

State of Science Summit- Breast Cancer: Chaired by Jennifer M. Matro, MD

March 9th 2023